Oculis to Present at BioCapital Europe
ZUG and LAUSANNE, Switzerland, March 9, 2023 – Oculis Holding AG (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that Riad Sherif, MD, Chief Executive Officer, will participate at BioCapital 2023, an event organized by EQT Life Sciences. The event is taking place in person, today, at Hotel Sofitel Legend The Grand Amsterdam. In addition to participating, Dr Sherif will be providing a corporate update scheduled at 2:20 p.m. CET.
To watch the event via livestream, please register here to receive the livestream link for the event.
About BioCapital Europe
BioCapital Europe is Europe’s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech, medtech and diagnostics companies from the Benelux and Europe.
About Oculis
Oculis is a global biopharmaceutical company (NASDAQ: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Contacts
Investor Relations
Dr. Riad Sherif, CEO
Media Relations
Consilium Strategic Communications
Amber Fennell, Tracy Cheung, David Daley